PA
ROIV icon

Parallel Advisors’s Roivant Sciences ROIV Stock Holding History

Parallel Advisors’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$72.7K Sell
2,054
-11
-0.5% -$325 ﹤0.01% 1908
2026
Q1 		$57.2K Buy
2,065
+520
+34% +$13.4K ﹤0.01% 1911
2025
Q4 		$33.5K Buy
1,545
+137
+10% +$2.7K ﹤0.01% 2049
2025
Q3 		$21.3K Buy
1,408
+60
+4% +$743 ﹤0.01% 2216
2025
Q2 		$15.2K Sell
1,348
-1,137
-46% -$12.3K ﹤0.01% 2309
2025
Q1 		$25.1K Buy
2,485
+1,108
+80% +$12K ﹤0.01% 2020
2024
Q4 		$16.3K Sell
1,377
-658
-32% -$7.78K ﹤0.01% 2233
2024
Q3 		$23.5K Buy
2,035
+1,735
+578% +$19.8K ﹤0.01% 2004
2024
Q2 		$3.17K Buy
300
+204
+213% +$2.23K ﹤0.01% 2666
2024
Q1 		$1.01K Buy
96
+13
+16% +$140 ﹤0.01% 2929
2023
Q4 		$932 Buy
83
+4
+5% +$39 ﹤0.01% 2949
2023
Q3 		$923 Buy
+79
New +$893 ﹤0.01% 2992

Other funds holding ROIV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $646M AUM 291.07% 1-Year Est. Return

Parallel Advisors's ROIV Position: Q2 2026 in Review

Parallel Advisors reduced its Roivant Sciences (ROIV) stake by 0.53% in Q2 2026, selling an estimated $325 and leaving 2,054 shares worth $72.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1908.

Parallel Advisors first reported a position in ROIV in Q3 2023 and has held it in 12 quarters since. 357 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Parallel Advisors held 2,054 shares of Roivant Sciences worth $72.7K as of Q2 2026.
  • Parallel Advisors sold 11 Roivant Sciences shares in Q2 2026, an estimated $325.
  • Roivant Sciences made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #1908 holding.
  • Parallel Advisors first reported a position in Roivant Sciences in Q3 2023 and has held it in 12 quarters since.
  • 357 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.